Description

Carbamic Acid, [2-[[3-(4-Chlorophenyl)-3,4-Dihydro-7-Hydroxy-2-(1-Methylethyl)-4-Oxo-8-Quinazolinyl]Oxy]Ethyl]-, 1,1-Dimethylethyl Ester (9Ci) is a complex, high-purity synthetic intermediate of significant interest in advanced pharmaceutical research and development. This compound matters as a key building block for the synthesis of novel therapeutic agents, particularly within the quinazolinone class, which is known for diverse biological activities. It is primarily needed by R&D chemists and process development scientists in the pharmaceutical, biotechnology, and fine chemical sectors working on new drug candidates.

Application

• Pharmaceutical Intermediate: Serves as a critical precursor in the multi-step synthesis of potential active pharmaceutical ingredients (APIs), especially those targeting specific enzyme pathways.
• Medicinal Chemistry Research: Used as a scaffold or building block for creating compound libraries in drug discovery programs focused on oncology, neurology, or inflammatory diseases.
• Process Chemistry Development: Employed in route scouting and optimization studies to develop efficient, scalable manufacturing processes for new chemical entities.
• Biochemical Tool Compound: May be utilized in vitro to study biological mechanisms and structure-activity relationships (SAR) of quinazolinone derivatives.
• Reference Standard: Can be supplied as a high-purity analytical standard for quality control and method development in analytical laboratories.
• Custom Synthesis Starting Material: Provides a specialized starting point for contract research organizations (CROs) and CDMOs performing bespoke synthesis for clients.

Basic Information

Product Name	Carbamic Acid, [2-[[3-(4-Chlorophenyl)-3,4-Dihydro-7-Hydroxy-2-(1-Methylethyl)-4-Oxo-8-Quinazolinyl]Oxy]Ethyl]-, 1,1-Dimethylethyl Ester (9Ci)
CAS No.	871814-46-9
Molecular Formula	C24H26ClN3O5
Molecular Weight	471.93 g/mol
Synonyms	tert-Butyl N-[2-({3-(4-chlorophenyl)-7-hydroxy-2-isopropyl-4-oxo-3,4-dihydroquinazolin-8-yl}oxy)ethyl]carbamate; 8-[2-[(tert-Butoxycarbonyl)amino]ethoxy]-3-(4-chlorophenyl)-7-hydroxy-2-(1-methylethyl)-4(3H)-quinazolinone; Carbamic acid, N-[2-[[3-(4-chlorophenyl)-7-hydroxy-2-(1-methylethyl)-4-oxo-3,4-dihydro-8-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester; 871814-46-9; UNII-9J8F8Y0H4B; 9J8F8Y0H4B
EINECS	Contact for details

Quality Control

Our Carbamic Acid, [2-[[3-(4-Chlorophenyl)-3,4-Dihydro-7-Hydroxy-2-(1-Methylethyl)-4-Oxo-8-Quinazolinyl]Oxy]Ethyl]-, 1,1-Dimethylethyl Ester (9Ci) is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity and identity confirmation (IR, NMR), to ensure it meets the stringent requirements of research and development applications. Certificates of Analysis (COA) detailing batch-specific results are provided and available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at controlled room temperature (15-25°C). Keep the container sealed to protect from moisture.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 97.0%
Loss on Drying	≤ 1.0%
Residue on Ignition	≤ 0.5%
Single Unknown Impurity (HPLC)	≤ 1.0%
Total Impurities (HPLC)	≤ 3.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.